(19)
(11) EP 3 941 467 A1

(12)

(43) Date of publication:
26.01.2022 Bulletin 2022/04

(21) Application number: 20772952.6

(22) Date of filing: 19.03.2020
(51) International Patent Classification (IPC): 
A61K 31/4418(2006.01)
C07K 16/28(2006.01)
 A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 31/519; A61K 31/444; C07K 16/2818; A61K 45/06; A61K 39/3955
 
C-Sets:
  1. A61K 39/3955, A61K 2300/00;
  2. A61K 31/444, A61K 2300/00;
  3. A61K 31/519, A61K 2300/00;
(86) International application number:
PCT/US2020/023722
(87) International publication number:
WO 2020/191240 (24.09.2020 Gazette 2020/39)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 19.03.2019 US 201916358329
19.12.2019 US 201962950780 P

(71) Applicants:
  • ChemoCentryx, Inc.
    San Carlos, CA 94070 (US)
  • UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Gainesville, FL 32611-5500 (US)

(72) Inventors:
  • CAMPBELL, James, J.
    San Jose, CA 95128 (US)
  • SINGH, Rajinder
    Belmont, CA 94002 (US)
  • HARRISON, Jeffrey, K.
    Gainesville, FL 32610 (US)

(74) Representative: Parchmann, Stefanie 
Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3
80335 München
80335 München (DE)

   


(54) COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR